Hema.to
hema.to is a deeptech AI company focused on revolutionizing immune medicine through AI-powered cytometry. Their solutions aim to provide precise diagnostics and optimal treatments tailored to individual immune systems by analyzing blood data. Their platform offers automated single-cell classification and population detection with a focus on reproducibility, reliability, and speed, being 2.2x faster than conventional methods. hema.to has developed products like hema.to BASE for general cytometry data analysis and hema.to B-NHL for diagnostic support in blood cancer. The company has secured €3.6M in financing and holds over 600,000 FCS files in its database, demonstrating significant traction and a commitment to advancing precision diagnostics in immunology.
Hema.to
hema.to is a deeptech AI company focused on revolutionizing immune medicine through AI-powered cytometry. Their solutions aim to provide precise diagnostics and optimal treatments tailored to individual immune systems by analyzing blood data. Their platform offers automated single-cell classification and population detection with a focus on reproducibility, reliability, and speed, being 2.2x faster than conventional methods. hema.to has developed products like hema.to BASE for general cytometry data analysis and hema.to B-NHL for diagnostic support in blood cancer. The company has secured €3.6M in financing and holds over 600,000 FCS files in its database, demonstrating significant traction and a commitment to advancing precision diagnostics in immunology.
TL;DR
Headquarters: Munich, Germany
Product focus: AI-powered automated flow cytometry analysis and diagnostic support
Notable traction: Database of >600,000 FCS files; claims >98% mean accuracy in a clinical study
Recent financing: Seed round Feb 2025; €3.6M reported
Company Overview
Problem Domain
Flow cytometry data analysis and diagnostic decision support in hemato-oncology and immunology.
Founded
2021
Industry
Biotechnology
Funding Track Record
€3.6M
Round included Elaia, Heal Capital, HTGF, Bayern Kapital and others
Investor Signal
“Backed by a mix of deeptech/health investors including LUMO labs, Elaia, Heal Capital, HTGF and Bayern Kapital”